Ellis Martin Report: Entheon Biomedical (CNSX:ENBI) CEO Timothy Ko on the Ethical Clinical Use of DMT for Treating Substance Abuse, Depression, Anxiety and More

Malibu, CA, Feb 16, 2021 AEST (ABN Newswire) - Join Ellis Martin for a conversation with Timothy Ko, the CEO of Entheon Biomedical (CNSX:ENBI) (ENTBF:OTCMKTS).

Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the 'untreatable case' and 'lost cause' from the norm to the exception.

The company is committed to the legal development of regulated, safe and effective therapies, and in educating the public and medical profession as to the efficacy of psychedelic protocols when clinically administered in the optimum set and setting.

To view the Interview, please visit:
https://www.abnnewswire.net/press/en/104434/entheon



About Entheon Biomedical

Entheon Biomedical Corp. (CNSX:ENBI) is a biotechnology research and development company interested in treating addiction and substance use disorders.

    

Contact

Entheon Biomedical Corp. Joseph Cullen, Investor Relations Telephone: +1 (778) 919-8615 Joe@entheonbiomedical.com W: www.entheonbiomedical.com

The Ellis Martin Report      
Entheon Biomedical

Social Media Share this Article

X/Twitter Facebook LinkedIn

  Print This Article

ABN Newswire This Page Viewed:  (Last 7 Days: 12) (Last 30 Days: 72) (Since Published: 7339) 

Related Industry Topics:

#Financial General#Mining#Gold#Copper